Prevalence of *APC* and *PTEN* Alterations in Urachal Cancer

Nikolett Nagy 1 · Henning Reis 2 · Boris Hadaschik 3 · Christian Niedworok 3 · Orsolya Módos 1 · Attila Szendrői 1 · Kriszta Birá 4 · Thomas Hager 2 · Thomas Herold 2 · Jason Ablat 5 · Peter C. Black 5 · Krzysztof Okon 6 · Yuri Tolkach 7 · Anita Csizmarik 1 · Csilla Oláh 1 · David Keresztes 1 · Felix Bremmer 8 · Nadine T. Gaisa 9 · József Tímár 12 · Marcell A. Szász 13 · Michael Rink 14 · Margit Fisch 14 · Péter Nyirády 1 · Tibor Szarvas 1,3

Received: 2 March 2020 / Accepted: 7 July 2020 / Published online: 4 August 2020 © The Author(s) 2020

**Abstract**

Urachal carcinoma (UrC) is a rare tumor with remarkable histological and molecular similarities to colorectal cancer (CRC). Adenomatous polyposis coli (*APC*) is the most frequently affected gene in CRC, but the prevalence and significance of its alterations in UrC is poorly understood. In addition, loss of phosphatase and tensin homologue (*PTEN*) was shown to be associated with therapy resistance in CRC. Our primary aim was to assess specific genetic alterations including *APC* and *PTEN* in a large series of UrC samples in order to identify clinically significant genomic alterations. We analyzed a total of 40 UrC cases. Targeted 5-gene (*APC*, *PTEN*, *DICER1*, *PRKAR1A*, *TSHR*, *WRN*) panel sequencing was performed on the Illumina MiSeq platform (*n* = 34). In addition, ß-catenin (*n* = 38) and *PTEN* (*n* = 30) expressions were assessed by immunohistochemistry. *APC* and *PTEN* genes were affected in 15% (5/34) and 6% (2/34) of cases. Two of five *APC* alterations (p.Y1075*, p.K1199*) were truncating pathogenic mutations. One of the two *PTEN* variants was a pathogenic frameshift insertion (p.C211fs). In 29% (11/38) of samples, at least some weak nuclear ß-catenin immunostaining was detected and *PTEN* loss was observed in 20% (6/30) of samples. The low prevalence of *APC* mutations in UrC represents a characteristic difference to CRC. Based on *APC* and ß-catenin results, the Wnt pathway seems to be rarely affected in UrC. Considering the formerly described involvement of *PTEN* protein loss in anti-EGFR therapy-resistance its immunohistochemical testing may have therapeutic relevance.

**Keywords** Urachal cancer · Colorectal cancer · Molecular genetics · Mutation · APC · ß-catenin
Introduction

The urachus is an extraperitoneal fibromuscular band that connects the bladder dome and the umbilicus. During fetal development, the urachus ensures the communication between the forming bladder and the allantois. After the fourth month of embryonic life, the urachus usually transforms into a fibromuscular strand (i.e., median umbilical ligament). In up to one third of adults, this obliteration can be incomplete resulting in microscopic urachal residues. Incomplete regression of the urachal structure may lead to various diseases including urachal cancer (UrC) [1, 2].

UrC is an extremely rare disease with an estimated annual incidence of one in one million adults. The majority of UrC present as adenocarcinomas (~90%) with mucinous, intestinal, signet ring, not otherwise specified (NOS) or mixed histology. Because of its hidden anatomical location, UrC is mostly detected in progressed stages when patients present with hematuria resulting from its invasion into the urinary bladder. At this advanced stage, the overall 5-year survival is only about 50% [3–5].

Although urachal and colorectal adenocarcinomas (CRC) are different types of cancer, they share remarkable histopathological and clinical similarities. Also, their immunophenotype shows overlapping staining characteristics with only a few exceptions [4]. In contrast to CRC, the molecular background of UrC is only poorly understood. Data on UrC’s mutational pattern further highlighted its similarity to CRC with overlapping mutational patterns such as in TP53, KRAS, SMAD4 and NRAS [6–12]. On the other hand, later studies also identified some significant molecular differences between UrC and CRC [6–12, 14–18].

In CRC, the adenomatous polyposis coli (APC) tumor suppressor gene has a critical role in the initiation of tumorigenesis. APC mutations lead to abnormal β-catenin accumulation in the nucleus. This nuclear β-catenin gets in contact with a member of the TCF/LEF family and acts as a transcriptional regulator on specific proliferation-associated target genes. APC mutations occur in more than 80% of CRC [17]. As a consequence, nuclear β-catenin expression can be observed in the generality of CRC making β-catenin a well established diagnostic and prognostic biomarker in CRC [19, 20]. The occurrence and role of APC-alterations and β-catenin-expression are less well established in UrC.

Phosphatase and tensin homolog (PTEN) is a leading negative regulator of the PI3K signaling pathway and therefore known as a tumorsuppressor gene. Its inactivating genetic mutations occur in up to 10% of CRCs [17]. In addition to genetic loss, PTEN is frequently downregulated by epigenetic silencing, leading to loss of PTEN expression [21]. Loss of PTEN protein expression was shown to be associated with resistance to anti-epidermal growth factor receptor (EGFR) therapy [22], while this therapy demonstrated effectiveness in UrC [14].

Therefore, we aimed to analyze relevant genetic alterations including the APC and PTEN genes as well as to assess the tissue protein expressions of β-catenin and PTEN in UrC.

Materials and Methods

Clinical Samples

Formalin-fixed paraffin embedded (FFPE) tumor tissues from 40 urachal adenocarcinoma patients were retrospectively collected from nine academic centers. Clinicopathological and follow-up data were retrieved from cooperating institutions using a uniform datasheet. Histopathological evaluation was performed according to criteria also adopted by the World Health Organization [23]. The study was performed in compliance with the Declaration of Helsinki and the institutional ethics committee approved the study protocol (16–6902-BO).

Sample Preparation and Targeted Next-Generation Sequencing

FFPE tumor tissue blocks were cut and 4 μm-thick slides were stained with hematoxylin and eosin. Tumor containing areas were marked by a pathologist (H.R.) and macrodissection was performed. Sample preparation and targeted next-generation sequencing were performed as previously described [7]. For targeted sequencing, a customized panel was used containing regions of interest. The customized panel contains exonic and flanking intronic regions from 6 genes (APC: exons 1–16, DICER1: exons 1–28, PRKAR1A: exons 1–11, PTEN: exons 1–9, TSHR: exons 1–10, WRN: exons 2–35). The regions were covered by a total of 108 amplicons. In all runs, an average coverage of approximately 5000x was obtained. Analyses were performed using CLC Biomedical Genomics Workbench.

Immunohistochemistry (IHC)

The β-catenin-IHC (Ref: 503–2264, Zytomed Systems, Berlin, Germany; pretreatment: CC1, 90 °C, 16 min; dilution: 1:1000, 24 min) analysis was performed on 38 FFPE tumor UrC tissues while PTEN-IHC (clone: 138G6, Cell Signaling Technology, Cambridge, UK; pretreatment: CC1, 90 °C, 32 min; dilution: 1:200, 24 min) analysis was done on 30 available FFPE tumor samples. For IHC assays, 3 μm thick FFPE sections were cut. IHC was performed on a Ventana Benchmark Ultra system (Ventana Medical Systems, Tucson, AZ, USA) and visualization was conducted using OptiView DAB System (Ventana Medical Systems).
Statistical Analysis

Statistical analyses were conducted with SPSS software package (v24 Chicago, IL). Kaplan-Meier survival analyses with the log-rank test were used to evaluate the impact of selected variables on overall survival. Furthermore, univariable Cox regression analyses were done. P values <0.05 were accounted statistically significant.

Results

Cohort Characteristics and Primary Treatment

The median age of patients at diagnosis was 51.5 years (range 24–78). Twenty-three patients (58%) were male and 17 (42%) were female. The most frequent symptom of UrC was haematuria reported in 83% of patients. Other symptoms included abdominal pain (10%) and palpable tumor mass (3%) (Table 1).

All UrC were adenocarcinomas (ADC) mostly of the intestinal subtype (48%) followed by the mucinous subtype (35%). Dominant signet ring cell features (>50% of tumor cells) were seen in 2 cases (5%) while calcification was observed in 4 cases (11%) (Table 1).

Based on its specific anatomical location and invasion pattern, UrC requires a unique stage classification. The most often used systems are the Sheldon and Mayo staging systems (23, 24). One patient was staged as Sheldon stage II (3%), 24 were stage III (63%) and 13 were stage IV (34%). According to the Mayo system 10 UrCs were stage I (28%), 13 stage II (36%), 4 stage III (11%) and 9 were stage IV (25%) tumors (Table 1).

In our cohort, one third of patients had lymph node positive or distant metastatic disease at initial diagnosis (14/40, 35%). Data on surgical treatment were available for 35 patients. Most patients (24/35, 69%) were treated with partial cystectomy followed by radical cystectomy (8/35, 23%), and transurethral resection (3/35, 9%), while removal of median umbilical ligament with umbilicus has been performed in 52% of cases (Table 1).

Genomic Alterations in Urachal Cancer

Sample purification in 34 of 40 cases yielded appropriate amount and quality of DNA sample for sequencing analysis. We analyzed the alterations of APC, DICER1, PRKARIA, PTEN, TSHR and WRN genes. The APC and PTEN genes were affected in 15% (5/34) and 6% (2/34) of cases. Two of the APC alterations (p.Y1075*, c.3225 T > G, p.K1199*; c.3595A > T) were truncating mutations resulting in a truncated and non-functional APC protein and were therefore considered as pathogenic, while other

| Table 1 Clinicopathological profile of 40 UrC cohort included in this study |
|---------------------------------------------------------------|
|               | n = 40 | (%)  |
| Sex             | Male    | 23   | 58           |
| Age (year)      | Median (Range) | 51.5 (24–78) |
| Haematuria      | Yes     | 25   | 83           |
|                 | No      | 5    | 17           |
|                 | n.a.    | 10   | –            |
| Abdominal pain  | Yes     | 3    | 10           |
|                 | No      | 26   | 90           |
|                 | n.a.    | 11   | –            |
| Palpable tumor  | Yes     | 1    | 3            |
|                 | No      | 29   | 97           |
|                 | n.a.    | 10   | –            |
| UrC type        | Intestinal | 19   | 48           |
|                 | Mucinous | 14   | 35           |
|                 | NOS     | 4    | 10           |
|                 | SRC     | 2    | 5            |
|                 | Mixed   | 1    | 3            |
| Calcification   | Yes     | 4    | 11           |
|                 | No      | 34   | 89           |
|                 | n.a.    | 2    | –            |
| Sheldon staging | I       | 0    | 0            |
|                 | II      | 1    | 3            |
|                 | III     | 24   | 63           |
|                 | IV      | 13   | 34           |
|                 | n.a.    | 2    | –            |
| Mayo staging    | I       | 10   | 28           |
|                 | II      | 13   | 36           |
|                 | III     | 4    | 11           |
|                 | IV      | 9    | 25           |
|                 | n.a.    | 4    | –            |
| LN status       | LN+     | 9    | 23           |
|                 | LN-/LNx | 31   | 78           |
| Distant metastasis | M+     | 11   | 28           |
|                 | M-/Mx   | 29   | 73           |
| LN/M status     | LN/M+   | 14   | 35           |
|                 | LN/M- / LN/Mx | 26   | 65           |
| Surgery         | TURB    | 3    | 9            |
|                 | Partial cystectomy | 24   | 69           |
|                 | Radical cystectomy | 8    | 23           |
|                 | n.a.    | 5    | –            |
| Umbilectomy     | Yes     | 16   | 52           |
|                 | No      | 15   | 48           |
|                 | n.a.    | 9    | –            |

Abbreviations: NOS not otherwise specified, SRC signet ring cell carcinoma, LN lymph node, LN+ positive lymph node status, LN- negative lymph node status, LNx unknown lymph node status, M+ positive distant metastatic status, M- negative distant metastatic status, Mx unknown distant metastatic status, TURB transurethral resection of bladder, n.a. not available
three **APC** alterations were annotated as benign variants (p.L2722V; c.8164C > G, p.L666V; c.1996 T > G, p.N862K; c.2586C > G) (Table 2). One of the two **PTEN** alterations was a frameshift insertion, leading to a dysfunctional protein (p.C2111fs; c.631_632insG) and was classified as a pathogenic mutation, while the other **PTEN** alteration was considered as benign (p.R308C; c.922C > T) (Table 2). In addition, **DICER1** intronic alterations (c.4206 + 8_4206 + 9insTTTG, COSM1666515) were found in 29% (10/34) of UrC cases.

**β-Catenin and PTEN Immunoexpression**

Immunohistochemistry for β-catenin was performed in 38 cases. Positive membranous and cytoplasmic β-catenin immunostaining was observed in 97% (37/38) of UrC samples. Any amount of clearly discernible nuclear immunostaining for β-catenin was detected in 29% (11/38) of samples. In one of the two cases with truncating **APC** mutation (p.Y1075*; c.3225 T > G), nuclear expression of β-catenin was observed. **PTEN** loss was observed in 6 of 30 (20%) UrC samples (Figs. 1 and 2).

**Survival Analysis**

The median overall survival (OS) was 34 months (range: 2–212 months) and the median progression-free survival (PFS) was 22 months (range 0–117 months). Three-year and five-year OS was 71% and 64%, respectively. Postoperative progression was detected in 50% of cases (16/31). At the time of data evaluation, 65% of patient (22/34) were alive.

Neither **APC** nor **PTEN** mutations were associated with OS, however these results must be interpreted with caution as only two cases demonstrated **APC** and **PTEN** mutations (Table 3) (Fig. 3a, c). Presence of nuclear β-catenin and loss of **PTEN** expressions were not associated with shorter OS (p = 0.606 and p = 0.869) (Fig. 3b, d).

### Table 2 Detected genomic alterations in UrC

| Gene     | Protein change | Nucleotide change | Prediction |
|----------|----------------|-------------------|------------|
| **APC**  | p.L2722V       | c.8164C > G       | Benign     |
| **APC**  | p.L666V        | c.1996 T > G      | Benign     |
| **APC**  | p.Y1075*       | c.3225 T > G      | Pathogenic |
| **APC**  | p.N862K        | c.2586C > G       | Benign     |
| **APC**  | p.K1199*       | c.3595A > T       | Pathogenic |
| **PTEN** | p.R308C        | c.922C > T        | Benign     |
| **PTEN** | p.C2111fs      | c.631_632insG     | Pathogenic |

**Discussion**

It is well known, that mutations of the **APC** tumor suppressor gene have a critical role already in early stages of CRC development. The most important function of **APC** is to establish an interaction with the β-catenin protein, thus accelerating its degradation and regulation of the cadherin-mediated cell–cell adhesion system. Functional loss of **APC** leads to abnormal β-catenin accumulation and translocation from the plasma membrane to the nucleus [20].

Singh et al. used a whole exome sequencing approach and found **APC** mutations in 43% (3/7) of UrC cases. They detected one sample with a nonsense mutation, one with a frameshift mutation and one with a deletion. The frameshift mutation and deletion caused dysfunctional **APC** proteins [16]. Collazo-Lorduy et al. described truncated **APC** mutations (R1450*, R554*) in 22% (2/9) of UrC samples using a targeted exome sequencing approach [14]. In addition, Lee et al. reported **APC** mutations in 18% (3/17) of UrC cases including a frameshift deletion (K1444fs) and a stop-gain single nucleotide variant (SNV) (E1093*) [10]. In the latest study, Kardos et al. performed targeted exon sequencing of 12 urachal adenocarcinoma cases and found 3 of 12 samples (25%) with **APC** mutations [9].

In our study, analyzing 34 UrC cases, deleterious alterations of **APC** tumor suppressor gene were present in 2 UrC samples. Neither mutation has been previously reported in UrC: p.Y1075* (c.3225 T > G), p.K1199* (c.3595A > T). Both of these nonsense mutations are predicted to cause a truncated, dysfunctional **APC** protein. Three additional alterations were considered benign. Presence of potentially pathogenic **APC** mutations tended to be associated with shorter OS, however, because of the low number of cases with **APC** mutation, this correlation has to be interpreted cautiously.

Summarizing our results with all currently available data on **APC** status in UrC, an overall number of 14 of 141 (10%) UrC samples exhibited **APC** alterations [6–16, 18, 24–26] which is in clear contrast to the high **APC** mutational rate (80%) found in CRC [17]. This finding represents a further characteristic difference in the molecular taxonomy between CRC and UrC. Therefore, our results demonstrate that the Wnt pathway is probably less frequently involved in the pathogenesis of UrC compared to CRC.

β-catenin is a well-established diagnostic and prognostic biomarker in CRC. Physiologically, β-catenin staining is restricted to the membrane/cytoplasm and is involved in cadherin-mediated cell-cell adhesion and gene transcription regulation. Nuclear β-catenin expression can be observed in CRC [19]. Wong et al. demonstrated positive nuclear staining for β-catenin expression in the vast majority of colorectal adenocarcinomas which reflects the high **APC** mutation rate found in CRC [27].
In a recent review of the UrC literature including own data, we found a low incidence of nuclear β-catenin staining in UrC (14%, 9/63) [4]. In the present study, we detected positive nuclear β-catenin immunostaining in 29% (11/38) of UrC samples. In addition, β-catenin nuclear expression was not associated with adverse OS ($p = 0.606$). Interestingly, we observed a nuclear β-catenin localization only in one of the two samples with truncating APC mutation. As a potential genetic mechanism for β-catenin nuclear accumulation, Alomar et al. identified an activating mutation in exon 3 of $CTNNBI$ (β-catenin) gene which resulted in an amino acid change at phosphorylation sites of glycogen synthase kinase-3 (GSK-3β). Failing of phosphorylation was found to decrease sequestration of β-catenin by APC [28]. This effect might explain our finding with low APC mutational frequency but at the same time surprising high rate (29%) of nuclear β-catenin positivity. It has also to be kept in mind that we used a 1% threshold for calling a case positive in case of nuclear β-catenin staining. In some cases, it is difficult to discriminate between a real nuclear staining event in the background of strong membranous/
cytoplasmic staining especially in smaller tumor cells (i.e. signet ring cells).

The tumor suppressor PTEN is a negative regulator of the PI3K signaling pathway. PTEN mutations occur in 4–10% of CRC and were suggested as potential markers of response to EGFR and mitogen-activated protein kinase (MAPK) inhibitor-based targeted therapies [17]. Perrone et al. showed that inactivation of PTEN protein by mutation (P103S, E99*) or deletion (hemizygous) was responsible of anti-EGFR resistance [29]. PTEN protein loss was detected in approximately 40% of all CRC patients, which is clearly higher compared to the rate of genomic loss. This suggests that PTEN is more frequently downregulated by epigenetic silencing. In accordance, PTEN methylation was found to be significantly correlated with PTEN expression [21]. Similar to the findings at the genomic level, Frattini et al. showed that loss of PTEN protein expression was associated with non-responsiveness to cetuximab [22].

In the literature, we found three whole exome sequencing studies with an overall number of 19 UrC samples. None of them reported any PTEN mutations [10, 14–16]. In addition, none of the targeted sequencing studies reported any PTEN mutations in UrC. Here, we identified a pathogenic frameshift PTEN mutation (p.C211fs) in one of the 34 UrC cancer samples (3%), suggesting a low incidence for PTEN mutation in UrC. Therefore, the PTEN mutational frequency in UrC seems to be similar to that of reported in CRC (4–10%) [17].

In the literature, we found three whole exome sequencing studies with an overall number of 19 UrC samples. None of them reported any PTEN mutations [10, 14–16]. In addition, none of the targeted sequencing studies reported any PTEN mutations in UrC. Here, we identified a pathogenic frameshift PTEN mutation (p.C211fs) in one of the 34 UrC cancer samples (3%), suggesting a low incidence for PTEN mutation in UrC. Therefore, the PTEN mutational frequency in UrC seems to be similar to that of reported in CRC (4–10%) [17].

In the literature, we found three whole exome sequencing studies with an overall number of 19 UrC samples. None of them reported any PTEN mutations [10, 14–16]. In addition, none of the targeted sequencing studies reported any PTEN mutations in UrC. Here, we identified a pathogenic frameshift PTEN mutation (p.C211fs) in one of the 34 UrC cancer samples (3%), suggesting a low incidence for PTEN mutation in UrC. Therefore, the PTEN mutational frequency in UrC seems to be similar to that of reported in CRC (4–10%) [17].

In the literature, we found three whole exome sequencing studies with an overall number of 19 UrC samples. None of them reported any PTEN mutations [10, 14–16]. In addition, none of the targeted sequencing studies reported any PTEN mutations in UrC. Here, we identified a pathogenic frameshift PTEN mutation (p.C211fs) in one of the 34 UrC cancer samples (3%), suggesting a low incidence for PTEN mutation in UrC. Therefore, the PTEN mutational frequency in UrC seems to be similar to that of reported in CRC (4–10%) [17].

Table 3 Univariate analysis

| Variables          | Overall survival |
|--------------------|------------------|
|                    | n    | HR  | 95% CI | P    |
| Sheldon stage      |      |     |        |      |
| I-III              | 25   | ref. |        |      |
| IV                 | 13   | 2.332| 0.734–7.407 | 0.151 |
| Mayo stage         |      |     |        |      |
| I-II               | 25   | ref. |        |      |
| III-IV             | 13   | 2.332| 0.734–7.407 | 0.151 |
| LN/M status        |      |     |        |      |
| LN/M- or LN/Mx     | 18   | ref. |        |      |
| LN/M+              | 13   | 1.982| 0.564–6.969 | 0.286 |
| PTEN mutations     |      |     |        |      |
| negative           | 32   | ref. |        |      |
| positive           | 2    | 2.124| 0.436–10.337 | 0.351 |
| PTEN staining      |      |     |        |      |
| present            | 24   | ref. |        |      |
| absent             | 6    | 1.144| 0.230–5.687 | 0.869 |
| APC status         |      |     |        |      |
| No mutation        | 32   | ref. |        |      |
| Mutation           | 2    | 3.464| 0.704–17.056 | 0.127 |
| β-Catenin nuclear staining | |     |        |      |
| negative           | 27   | ref. |        |      |
| positive           | 11   | 0.722| 0.209–2.500 | 0.607 |

Abbreviations: LN/M+ positive lymph node or distant metastasis status, LN/M- negative lymph node and distant metastasis status, LN/Mx unknown lymph node or distant metastasis status

The tumor suppressor PTEN is a negative regulator of the PI3K signaling pathway. PTEN mutations occur in 4–10% of CRC and were suggested as potential markers of response to EGFR and mitogen-activated protein kinase (MAPK) inhibitor-based targeted therapies [17]. Perrone et al. showed that inactivation of PTEN protein by mutation (P103S, E99*) or deletion (hemizygous) was responsible of anti-EGFR resistance [29]. PTEN protein loss was detected in approximately 40% of all CRC patients, which is clearly higher compared to the rate of genomic loss. This suggests that PTEN is more frequently downregulated by epigenetic silencing. In accordance, PTEN methylation was found to be significantly correlated with PTEN expression [21]. Similar to the findings at the genomic level, Frattini et al. showed that loss of PTEN protein expression was associated with non-responsiveness to cetuximab [22].
predominantly silenced by epigenetic downregulation in UrC [21]. The high rate of PTEN protein loss in UrC suggests that its immunohistochemical analysis may be important in order to predict potential inresponsiveness to anti-EGFR therapy. In contrast, the rare occurrence of PTEN inactivating mutations suggests that these alterations are less important to analyze when considering the administration of an anti-EGFR drug, while activating KRAS mutations are more common in UrC (28%) and are clinically important negative predictors of anti-EGFR therapy [6–16, 18, 24–26].

Conclusions

In summary, we analyzed a large cohort of UrC with a targeted next-generation sequencing approach supplemented with β-catenin and PTEN immunohistochemical analyses. Our results show that APC mutations are much less frequent in UrC (10%) compared to CRC (80%) suggesting that the Wnt pathway is involved in the pathogenesis of only a relatively small portion of UrC. In addition, both UrC and CRC have low rates genomic loss (3% and 4–10%) but relative high rates of PTEN protein loss (20% and 40%), suggesting an epigenetic regulation for this gene in both tumor types. Therefore, as the loss of PTEN protein expression was found to be associated with resistance against anti-EGFR therapy, its immunohistochemical testing should be considered when planning anti-EGFR therapy. Our data provides further clues for both the similarity (regarding PTEN) and difference (regarding APC) between UrC and CRC and suggest that these tumor types are similar yet distinct on the molecular level.

Acknowledgments

Tibor Szarvas was supported by János Bolyai Research Scholarship of the Hungarian Academy of Sciences. This work was supported by the National Research, Development and Innovation Office – NKFIH / PD 115616 and NVKP_16-1-2016-004.

Funding Information

Open access funding provided by Semmelweis University.

Compliance with Ethical Standards

Declarations of Interest None.
Conflict of Interest The authors declare no conflicts of interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Schubert GE, Pavkovic MB, Betteke-Beudertig BA (1982) Tubular urachal remnants in adult bladders. J Urol 127(1):40–42
2. Amin MB, Smith SC, Eble JN, Rao P, Choi WWL, Tamboli P, Young RH (2014) Glandular neoplasms of the urachus: a report of 55 cases emphasizing mucinous cystic tumors with proposed classification. Am J Surg Pathol 38(8):1033–1045. https://doi.org/10.1097/PAS.0000000000000250
3. Kumar N, Khosla D, Kumar R, Mandal AK, Saikia UN, Kapoor R, Singh SK, Sharma SC (2014) Urachal carcinoma: clinicopathological features, treatment and outcome. J Cancer Res Ther 10(3):571–574. https://doi.org/10.4103/0973-1482.137955
4. Reis H, Kraft U, Niedworok C, Módos O, Herold T, Behrendt M, al-Ahmadi H, Hadaszchik B, Nyirády P, Szarvas T (2018) Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data. Dis Markers:7308168. https://doi.org/10.1155/2018/7308168
5. Szarvas T, Módos O, Niedworok C et al (2016) Clinical, prognostic, and therapeutic aspects of urachal carcinoma—a comprehensive review with meta-analysis of 1,010 cases. Urol Oncol 34(9):388–398. https://doi.org/10.1016/j.uroon.2016.04.012
6. Riva G, Mian C, Luchini C, Girolami I, Ghimenton C, Cima L, Novelli L, Hanspeter E, Mazzoloni G, Schwienbacher C, Pycha S, D’Elia C, Trenti E, Pycha A, Martignon G, Hes O, Eecher A, Nesi G, Brunelli M (2019) Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis. Virchows Arch 474(1):13–20. https://doi.org/10.1007/s00428-018-2467-1
7. Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Brenner F, Gaiss NT, Chlosta P, Kriegsmann J, Timar J, Kristiansen G, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T (2018) Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas. Int J Cancer 143:1764–1773. https://doi.org/10.1002/ijc.31547
8. Módos O, Reis H, Niedworok C et al (2016) Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurrence and prognostic significance. Oncotarget 7(26):39293–39301. https://doi.org/10.18632/oncotarget.9828
9. Kardos J, Wobker SE, Woods ME, Nielsen ME, Smith AB, Wallen EM, Pruthi RS, Hayward MC, McGinty KA, Grilley-Olson JE, Patel NM, Weck KE, Black P, Parker JS, Milowsky MI, Hayes DN, Kim WY (2017) Comprehensive molecular characterization of Urachal adenocarcinoma reveals commonalities with colorectal Cancer, including a Hypermutable phenotype. JCO Prec Oncol 1(1):1–12. https://doi.org/10.1200/PO.17.00027
10. Lee S, Lee J, Sim SH, Lee Y, Moon KC, Lee C, Park WY, Kim NKD, Lee SH, Lee H (2017) Comprehensive somatic genome alterations of urachal carcinoma. J Med Genet 54(8):572–578. https://doi.org/10.1136/jmedgenet-2016-104390
11. Hang JF, Pan CC (2017) Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma. Pathology. 49(3):316–317. https://doi.org/10.1016/j.pathol.2016.11.017
12. Srinirupan SJ, Ward M, Woo J, Cimic A (2014) High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations. Hum Pathol 45(2):327–330. https://doi.org/10.1016/j.humpath.2013.09.008
13. Loh KP, Mondo E, Hansen EA, Sievert L, Fung C, Sahasrabudhe DM, Guancial E (2016) Targeted therapy based on tumor genomic analyses in metastatic Urachal carcinoma. Clin Genitourin Cancer 14(4):e449–e452. https://doi.org/10.1016/j.clgc.2016.03.013
14. Collazo-Lorduy A, Castillo-Martín M, Wang L, Patel V, Iyer G, Jordan E, al-Ahmadi H, Leonid I, Oh WK, Zhu J, McBride RB, Cordon-Cardo C, Solit DB, Sfakianos JP, Galsky MD (2016) Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. Eur Urol 70(5):771–775. https://doi.org/10.1016/j.eururo.2016.04.037
15. Cha S, Lee J, Shin JY, Kim JY, Kim SH, Keam B, Kim TM, Kim DW, Heo DS, Lee SH, Kim Ji (2016) Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastatic. BMC Cancer 16:170. https://doi.org/10.1186/s12885-016-2209-1
16. Singh H, Liu Y, Xiao X et al (2016) Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations. Oncotarget 7(20):29211–29215. https://doi.org/10.18632/oncotarget.8640
17. Cancer Genome Atlas N (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487(7407):330–337. https://doi.org/10.1038/nature11252
18. Cornejo KM, Paner GP, Tomaszewicz K et al (2016) Mutational profile using next generation sequencing may aid in distinguishing Urachal adenocarcinoma from bladder adenocarcinoma nature modern pathology, 105th annual meeting of the United States and Canadian academy of pathology (USCAP), 2015, Seattle. Washington. 29:528–556. https://doi.org/10.1038/modpathol.2016.28
19. Roy S, Smith MA, Cielyp KM, Acqualonida MB, Parwani AV (2012) Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge. Diaogn Pathol 7:151. https://doi.org/10.1186/1746-1596-7-151
20. Aoki K, Taklto MM (2007) Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci 120(19):3327–3335. https://doi.org/10.1242/jcs.03485
21. Yazdani Y, Farazmandfar T, Azadeh H, Zekavatian Z (2016) The prognostic effect of PTEN expression status in colorectal cancer patients with metastasis. Br J Cancer 97(8):1139. https://doi.org/10.1038/bjc.2016.86
22. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97(8):1139–1145. https://doi.org/10.1038/sj.bjc.6604009
23. Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE (1984) Malignant urachal lesions. J Urol 131(1):1–8
24. Toubaji A, Jordan EJ, Desai N et al (2016) Genomic Alterations in Primary Bladder Adenocarcinoma and Urachal Adenocarcinoma. Nature Modern Pathology, 106th Annual Meeting of the United

N. Nagy et al.
25. Pires-Luis A, Martinek P, Filipovic J et al (2018) Primary adenocarcinoma of the urinary bladder: next-generation sequencing (NGS) of non-urachal enteric-type adenocarcinomas, Urachal adenocarcinomas, mucinous adenocarcinomas, and colonic Metaplasias/adenomas. Drugs Future 43:359. https://doi.org/10.1358/dof.2018.043.052808557

26. Lee B, Jordan E, Won H, Bagrodia A, Desai N, Bajorin D, Rosenberg J, Bochner B, Kim W, Berger M, Solit D, al-Ahmadie H, Iyer G (2016) Mutational landscape of primary bladder and Urachal adenocarcinoma. J Urol 195(4S):e1133–e1144. https://doi.org/10.1016/j.juro.2016.02.2431

27. Wong SZ, Lo E, Lee K et al (2004) Prognostic and diagnostic significance of β-catenin nuclear Immunostaining in colorectal Cancer. Clin Cancer Res 10(4):1401–1408. https://doi.org/10.1158/1078-0432.CCR-0157-03

28. Alomar SY, Mansour L, Abuderman A, Alkhuriji A, Arafah M, Alwasel S, Harrath AH, Almutairi M, Trayhym P, Dar JA (2016) β-Catenin accumulation and S33F mutation of CTNNB1 gene in colorectal cancer in Saudi Arabia. Pol J Pathol 67(2):156–162. https://doi.org/10.5114/pjp.2016.61452

29. Perrone F, Lampis A, Orsenigo M, di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S (2009) PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20(1):84–90. https://doi.org/10.1093/annonc/mdn541

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.